Discrepancy between serum leptin values and total body fat in response to the oral growth hormone secretagogue MK-677.

Svensson J, Carlsson B, Carlsson LM, Jansson JO, Bengtsson BA

Clinical endocrinology1 Apr 1999Cited by 5 (Europe PMC)

PMID10468903DOI10.1046/j.1365-2265.1999.00667.xPepBankPUB-10468903

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanRandomized controlled trialEfficacy outcome
In healthy obese males, MK‑677 increased serum leptin at 2 weeks versus placebo.
In plain wordsIn obese men, MK‑677 increased serum leptin more than placebo at 2 weeks.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseSerum leptin at 2 weeks
Study
n = 24
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
25 mg/day · oral · 8 weeksAs given in this study (human).
Measurements
P value for Serum leptin, MK-677 versus placebo at 2 weeks
< 0.05 p value
Serum leptin, MK-677 versus placebo at 2 weeks
Source sentences
Summary
MK-677 treatment increased serum leptin levels and leptin/body fat ratio at 2 weeks of treatment (P < 0.05 vs. placebo) but no significant change was observed at 8 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized, double-blind, and parallel study.
Summary · context
Twenty-four healthy obese males, 19-49 years of age, with body mass index (BMI) > 30 kg/m2 and a waist:hip ratio > 0.95, were treated with MK-677 (25 mg/day; n = 12) or placebo (n = 12) for 8 weeks.
Report a problemFND-1046890301
02HumanRandomized controlled trialEfficacy outcome
In healthy obese males, MK‑677 increased the leptin/body fat ratio at 2 weeks versus placebo.
In plain wordsIn obese men, MK‑677 increased the leptin-to-body-fat ratio more than placebo at 2 weeks.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseLeptin/body fat ratio at 2 weeks
Study
n = 24
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
25 mg/day · oral · 8 weeksAs given in this study (human).
Measurements
P value for Leptin/body fat ratio, MK-677 versus placebo at 2 weeks
< 0.05 p value
Leptin/body fat ratio, MK-677 versus placebo at 2 weeks
Source sentences
Summary
MK-677 treatment increased serum leptin levels and leptin/body fat ratio at 2 weeks of treatment (P < 0.05 vs. placebo) but no significant change was observed at 8 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized, double-blind, and parallel study.
Summary · context
Twenty-four healthy obese males, 19-49 years of age, with body mass index (BMI) > 30 kg/m2 and a waist:hip ratio > 0.95, were treated with MK-677 (25 mg/day; n = 12) or placebo (n = 12) for 8 weeks.
Report a problemFND-1046890302
03HumanRandomized controlled trialEfficacy outcome
In healthy obese males, MK‑677 did not significantly change serum leptin at 8 weeks versus placebo.
In plain wordsIn obese men, MK‑677 did not significantly change leptin compared with placebo at 8 weeks.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changeSerum leptin at 8 weeks
Study
n = 24
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
25 mg/day · oral · 8 weeksAs given in this study (human).
Source sentences
Summary
MK-677 treatment increased serum leptin levels and leptin/body fat ratio at 2 weeks of treatment (P < 0.05 vs. placebo) but no significant change was observed at 8 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized, double-blind, and parallel study.
Summary · context
Twenty-four healthy obese males, 19-49 years of age, with body mass index (BMI) > 30 kg/m2 and a waist:hip ratio > 0.95, were treated with MK-677 (25 mg/day; n = 12) or placebo (n = 12) for 8 weeks.
Report a problemFND-1046890303
04HumanRandomized controlled trialEfficacy outcome
In healthy obese males, MK‑677 did not significantly change the leptin/body fat ratio at 8 weeks versus placebo.
In plain wordsIn obese men, MK‑677 did not significantly change the leptin-to-body-fat ratio compared with placebo at 8 weeks.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changeLeptin/body fat ratio at 8 weeks
Study
n = 24
Comparator
Placebo
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
25 mg/day · oral · 8 weeksAs given in this study (human).
Source sentences
Summary
MK-677 treatment increased serum leptin levels and leptin/body fat ratio at 2 weeks of treatment (P < 0.05 vs. placebo) but no significant change was observed at 8 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized, double-blind, and parallel study.
Summary · context
Twenty-four healthy obese males, 19-49 years of age, with body mass index (BMI) > 30 kg/m2 and a waist:hip ratio > 0.95, were treated with MK-677 (25 mg/day; n = 12) or placebo (n = 12) for 8 weeks.
Report a problemFND-1046890304
05HumanRandomized controlled trialEfficacy outcome
In healthy obese males, MK‑677 increased serum free T3 at 8 weeks versus placebo.
In plain wordsIn obese men, MK‑677 increased free T3 more than placebo at 8 weeks.
Peptide
MK-677 (ibutamoren)
Outcome
IncreaseFree T3 at 8 weeks
Study
n = 24
Comparator
Placebo
Outcome group
Thyroid function · Endocrine and hormones
Studied dose
25 mg/day · oral · 8 weeksAs given in this study (human).
Measurements
P value for Serum free T3, MK-677 versus placebo at 8 weeks
< 0.05 p value
Serum free T3, MK-677 versus placebo at 8 weeks
Source sentences
Summary
An increase in serum free 3, 5, 3'-triiodothyronine (free T3) was not detected until 8 weeks of MK-677 treatment (P < 0.05 vs. placebo).
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized, double-blind, and parallel study.
Summary · context
Twenty-four healthy obese males, 19-49 years of age, with body mass index (BMI) > 30 kg/m2 and a waist:hip ratio > 0.95, were treated with MK-677 (25 mg/day; n = 12) or placebo (n = 12) for 8 weeks.
Report a problemFND-1046890306
06HumanRandomized controlled trialEfficacy outcome
In healthy obese males, peak TSH after MK‑677 resembled placebo at initiation and at 2 weeks.
In plain wordsIn obese men, peak TSH with MK‑677 was similar to placebo at initiation and at 2 weeks.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changePeak TSH at initiation and 2 weeks
Study
n = 24
Comparator
Placebo
Outcome group
Thyroid function · Endocrine and hormones
Studied dose
25 mg/day · oral · 8 weeksAs given in this study (human).
Source sentences
Summary
Peak serum thyroid stimulating hormone (TSH) concentration after MK-677 administration was similar to that after placebo administration at initiation of treatment and at 2 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized, double-blind, and parallel study.
Summary · context
Twenty-four healthy obese males, 19-49 years of age, with body mass index (BMI) > 30 kg/m2 and a waist:hip ratio > 0.95, were treated with MK-677 (25 mg/day; n = 12) or placebo (n = 12) for 8 weeks.
Report a problemFND-1046890307
07HumanRandomized controlled trialEfficacy outcome
In healthy obese males, MK‑677 increased peak TSH at 8 weeks versus placebo, while values remained within the normal range.
In plain wordsIn obese men, MK‑677 increased peak TSH more than placebo at 8 weeks, within the normal range.
Peptide
MK-677 (ibutamoren)
Outcome
IncreasePeak TSH at 8 weeks
Study
n = 24
Comparator
Placebo
Outcome group
Thyroid function · Endocrine and hormones
Studied dose
25 mg/day · oral · 8 weeksAs given in this study (human).
Measurements
P value for Mean peak serum TSH, MK-677 versus placebo at 8 weeks
< 0.05 p value
Mean peak serum TSH, MK-677 versus placebo at 8 weeks
Source sentences
Summary
At 8 weeks of MK-677 treatment, mean peak serum TSH concentration was increased (P < 0.05 vs. placebo) although it remained within the normal range.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized, double-blind, and parallel study.
Summary · context
Twenty-four healthy obese males, 19-49 years of age, with body mass index (BMI) > 30 kg/m2 and a waist:hip ratio > 0.95, were treated with MK-677 (25 mg/day; n = 12) or placebo (n = 12) for 8 weeks.
Report a problemFND-1046890308
08HumanRandomized controlled trialEfficacy outcome
In healthy obese males, peak LH was similar after MK‑677 and placebo.
In plain wordsIn obese men, peak LH with MK‑677 was similar to placebo.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changePeak LH
Study
n = 24
Comparator
Placebo
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
25 mg/day · oral · 8 weeksAs given in this study (human).
Source sentences
Summary
Serum peak values of luteinizing hormone (LH) and follicle stimulating hormone (FSH) were similar after MK-677 and placebo administration.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized, double-blind, and parallel study.
Summary · context
Twenty-four healthy obese males, 19-49 years of age, with body mass index (BMI) > 30 kg/m2 and a waist:hip ratio > 0.95, were treated with MK-677 (25 mg/day; n = 12) or placebo (n = 12) for 8 weeks.
Report a problemFND-1046890309
09HumanRandomized controlled trialEfficacy outcome
In healthy obese males, peak FSH was similar after MK‑677 and placebo.
In plain wordsIn obese men, peak FSH with MK‑677 was similar to placebo.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changePeak FSH
Study
n = 24
Comparator
Placebo
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
25 mg/day · oral · 8 weeksAs given in this study (human).
Source sentences
Summary
Serum peak values of luteinizing hormone (LH) and follicle stimulating hormone (FSH) were similar after MK-677 and placebo administration.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized, double-blind, and parallel study.
Summary · context
Twenty-four healthy obese males, 19-49 years of age, with body mass index (BMI) > 30 kg/m2 and a waist:hip ratio > 0.95, were treated with MK-677 (25 mg/day; n = 12) or placebo (n = 12) for 8 weeks.
Report a problemFND-1046890310
10HumanRandomized controlled trialEfficacy outcome
In healthy obese males, MK‑677 reduced serum total testosterone versus placebo.
In plain wordsIn obese men, MK‑677 reduced total testosterone more than placebo.
Peptide
MK-677 (ibutamoren)
Outcome
DecreaseTotal testosterone
Study
n = 24
Comparator
Placebo
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
25 mg/day · oral · 8 weeksAs given in this study (human).
Measurements
P value for total testosterone reduction
< 0.05 unitless
MK-677 vs. placebo
Source sentences
Summary
MK-677 treatment reduced serum total testosterone (P < 0.05 vs. placebo) although total testosterone/sex hormone-binding globulin (SHBG) ratio (an index of free testosterone) was not changed.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized, double-blind, and parallel study.
Summary · context
Twenty-four healthy obese males, 19-49 years of age, with body mass index (BMI) > 30 kg/m2 and a waist:hip ratio > 0.95, were treated with MK-677 (25 mg/day; n = 12) or placebo (n = 12) for 8 weeks.
Report a problemFND-1046890311
11HumanRandomized controlled trialEfficacy outcome
In healthy obese males, MK‑677 did not change the total testosterone/SHBG ratio.
In plain wordsIn obese men, MK‑677 did not change the testosterone-to-SHBG ratio compared with placebo.
Peptide
MK-677 (ibutamoren)
Outcome
No significant changeTotal testosterone/SHBG ratio
Study
n = 24
Comparator
Placebo
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
25 mg/day · oral · 8 weeksAs given in this study (human).
Source sentences
Summary
MK-677 treatment reduced serum total testosterone (P < 0.05 vs. placebo) although total testosterone/sex hormone-binding globulin (SHBG) ratio (an index of free testosterone) was not changed.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized, double-blind, and parallel study.
Summary · context
Twenty-four healthy obese males, 19-49 years of age, with body mass index (BMI) > 30 kg/m2 and a waist:hip ratio > 0.95, were treated with MK-677 (25 mg/day; n = 12) or placebo (n = 12) for 8 weeks.
Report a problemFND-1046890312

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.